James K Liao

List of Publications by Year in Descending Order

103 papers	13,187 citations	49 h-index	107 g-index
107 ext. papers	14,398 ext. citations	7.6 avg, IF	6.77 L-index

#	Paper	IF	Citations
103	Rho Kinase regulates neutrophil NET formation that is involved in UVB-induced skin inflammation.. *Theranostics*, **2022**, 12, 2133-2149	12.1	2
102	Vascular Stiffening Mediated by Rho-Associated Coiled-Coil Containing Kinase Isoforms. *Journal of the American Heart Association*, **2021**, 10, e022568	6	1
101	Increase in Blood-Brain Barrier (BBB) Permeability Is Regulated by MMP3 via the ERK Signaling Pathway. *Oxidative Medicine and Cellular Longevity*, **2021**, 2021, 6655122	6.7	5
100	SALAD-BAAR: A numerical risk score for hospital admission or emergency department presentation in ambulatory patients with cardiovascular disease. *Clinical Cardiology*, **2021**, 44, 193-199	3.3	1
99	Emerging views of statin pleiotropy and cholesterol lowering. *Cardiovascular Research*, **2021**,	9.9	8
98	Serine-threonine kinase ROCK2 regulates germinal center B cell positioning and cholesterol biosynthesis. *Journal of Clinical Investigation*, **2020**, 130, 3654-3670	15.9	9
97	Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening. *Expert Opinion on Therapeutic Targets*, **2020**, 24, 47-62	6.4	13
96	Community Health Workers Reduce Rehospitalizations and Emergency Department Visits for Low-Socioeconomic Urban Patients With Heart Failure. *Critical Pathways in Cardiology*, **2020**, 19, 139-145	1.3	1
95	Regulator of G-Protein Signaling 5 Maintains Brain Endothelial Cell Function in Focal Cerebral Ischemia. *Journal of the American Heart Association*, **2020**, 9, e017533	6	7
94	A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease. *Translational Stroke Research*, **2020**, 11, 365-376	7.8	9
93	Association of Rising Violent Crime With Blood Pressure and Cardiovascular Risk: Longitudinal Evidence From Chicago, 2014-2016. *American Journal of Hypertension*, **2019**, 32, 1192-1198	2.3	5
92	Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease. *Stroke*, **2019**, 50, 738-744	6.7	23
91	The Pleiotropic Effects of Statins - From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia. *Current Vascular Pharmacology*, **2019**, 17, 222-232	3.3	33
90	Eplerenone improves endothelial function and arterial stiffness and inhibits Rho-associated kinase activity in patients with idiopathic hyperaldosteronism: a pilot study. *Journal of Hypertension*, **2019**, 37, 1083-1095	1.9	4
89	Tumor necrosis factor-levels and non-surgical bleeding in continuous-flow left ventricular assist devices. *Journal of Heart and Lung Transplantation*, **2018**, 37, 107-115	5.8	36
88	Neuroprotection Mediated by Upregulation of Endothelial Nitric Oxide Synthase in Rho-Associated, Coiled-Coil-Containing Kinase 2 Deficient Mice. *Circulation Journal*, **2018**, 82, 1195-1204	2.9	9
87	ABL Tyrosine Kinase Inhibitors (TKIs) Are Associated with Increased Rho-Associated Kinase (ROCK) Activity That May Contribute to Vascular Toxicity in Patients with Chronic Myeloid Leukemia (CML). *Blood*, **2018**, 132, 1739-1739	2.2	0

86	The Rho Kinase Isoforms ROCK1 and ROCK2 Each Contribute to the Development of Experimental Pulmonary Fibrosis. *American Journal of Respiratory Cell and Molecular Biology*, **2018**, 58, 471-481	5.7	55
85	Pleiotropic Effects of Statins on the Cardiovascular System. *Circulation Research*, **2017**, 120, 229-243	15.7	514
84	Decreased thromboembolic stroke but not atherosclerosis or vascular remodelling in mice with ROCK2-deficient platelets. *Cardiovascular Research*, **2017**, 113, 1307-1317	9.9	15
83	Cardiology Consultation in the Emergency Department Reduces Re-hospitalizations for Low-Socioeconomic Patients with Acute Decompensated Heart Failure. *American Journal of Medicine*, **2017**, 130, 1112.e17-1112.e31	2.4	11
82	ROCK as a therapeutic target for ischemic stroke. *Expert Review of Neurotherapeutics*, **2017**, 17, 1167-1177	4.3	30
81	RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. *Stroke*, **2017**, 48, 187-194	6.7	63
80	Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction. *JCI Insight*, **2017**, 2,	9.9	43
79	Elevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding. *Circulation*, **2016**, 134, 141-52	16.7	87
78	Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. *Scientific Reports*, **2016**, 6, 24578	4.9	27
77	RhoA/Rho-Associated Kinase as Marker of Cardiovascular Health **2016**, 739-769		
76	Rho Kinases and Cardiac Remodeling. *Circulation Journal*, **2016**, 80, 1491-8	2.9	73
75	MnTBAP increases BMPR-II expression in endothelial cells and attenuates vascular inflammation. *Vascular Pharmacology*, **2016**, 84, 67-73	5.9	5
74	MnTBAP stimulates angiogenic functions in endothelial cells through mitofusin-1. *Vascular Pharmacology*, **2015**, 72, 163-71	5.9	7
73	Exogenous nitric oxide inhibits Rho-associated kinase activity in patients with angina pectoris: a randomized controlled trial. *Hypertension Research*, **2015**, 38, 485-90	4.7	5
72	Two functional polymorphisms of ROCK2 enhance arterial stiffening through inhibiting its activity and expression. *Journal of Molecular and Cellular Cardiology*, **2015**, 79, 180-6	5.8	8
71	The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. *Pharmacological Reviews*, **2015**, 67, 103-17	22.5	119
70	ROCK insufficiency attenuates ozone-induced airway hyperresponsiveness in mice. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2015**, 309, L736-46	5.8	24
69	Interventional Transcatheter Closure Ameliorates the Leukocyte Rho Kinase Activities among Patients with Patent Ductus Arteriosus. *Acta Cardiologica Sinica*, **2015**, 31, 494-9	1.1	

68	RhoA/Rho-Associated Kinase as Marker of Cardiovascular Health **2015**, 1-31		
67	Evidence of pleiotropy by statins: leukocyte Rho kinase (ROCK) activity and pretreated statin before percutaneous coronary interventions are clinical vascular outcome predictors. *International Journal of Cardiology*, **2014**, 176, 250-3	3.2	4
66	Gene variations of ROCKs and risk of ischaemic stroke: the Women's Genome Health Study. *Clinical Science*, **2014**, 126, 829-835	6.5	13
65	Potential serum biomarkers in the pathophysiological processes of stroke. *Expert Review of Neurotherapeutics*, **2014**, 14, 173-85	4.3	35
64	Critical role of exogenous nitric oxide in ROCK activity in vascular smooth muscle cells. *PLoS ONE*, **2014**, 9, e109017	3.7	17
63	A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndrome. *International Journal of Cardiology*, **2013**, 167, 2813-9	3.2	14
62	Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 1591-600	9.4	58
61	FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2. *FASEB Journal*, **2013**, 27, 1439-49	0.9	64
60	Linking endothelial dysfunction with endothelial cell activation. *Journal of Clinical Investigation*, **2013**, 123, 540-1	15.9	232
59	Increased leukocyte Rho-associated coiled-coil containing protein kinase activity predicts the presence and severity of coronary vasospastic angina. *Atherosclerosis*, **2012**, 221, 521-6	3.1	25
58	Increased Rho kinase activity in congestive heart failure. *European Journal of Heart Failure*, **2012**, 14, 965-73	12.3	33
57	Inhibition of Rho-kinase attenuates endothelial-leukocyte interaction during ischemia-reperfusion injury. *Vascular Medicine*, **2012**, 17, 379-85	3.3	15
56	Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. *Trends in Pharmacological Sciences*, **2011**, 32, 167-73	13.2	119
55	Calcium channel blocker and Rho-associated kinase activity in patients with hypertension. *Journal of Hypertension*, **2011**, 29, 373-9	1.9	40
54	Fingolimod provides long-term protection in rodent models of cerebral ischemia. *Annals of Neurology*, **2011**, 69, 119-29	9.4	213
53	Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins?. *Circulation*, **2011**, 123, 1925-8	16.7	17
52	Novel aspects of the roles of Rac1 GTPase in the cardiovascular system. *Current Opinion in Pharmacology*, **2010**, 10, 116-21	5.1	48
51	Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. *Journal of Clinical Investigation*, **2010**, 120, 3280-95	15.9	164

50	Response to Letters Regarding Article, Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation *Circulation*, **2009**, 120,	16.7	1
49	Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. *Circulation*, **2009**, 119, 131-8	16.7	179
48	Increased leukocyte ROCK activity in patients after acute ischemic stroke. *Brain Research*, **2009**, 1257, 89-93	3.7	43
47	Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. *American Journal of Cardiology*, **2009**, 103, 437-41	3	61
46	Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *Current Atherosclerosis Reports*, **2009**, 11, 243-4	6	9
45	Genetically elevated C-reactive protein and ischemic vascular disease. *Current Atherosclerosis Reports*, **2009**, 11, 245	6	6
44	Statins inhibit Rho kinase activity in patients with atherosclerosis. *Atherosclerosis*, **2009**, 205, 517-21	3.1	97
43	Rho kinase: an important mediator of atherosclerosis and vascular disease. *Current Pharmaceutical Design*, **2009**, 15, 3108-15	3.3	86
42	Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. *Trends in Molecular Medicine*, **2008**, 14, 37-44	11.5	428
41	Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/- mice. *FASEB Journal*, **2008**, 22, 3561-70	0.9	59
40	Is statin discontinuation an option in patients who have had a stroke?. *Nature Clinical Practice Neurology*, **2008**, 4, 18-9		
39	A method for measuring Rho kinase activity in tissues and cells. *Methods in Enzymology*, **2008**, 439, 181-9	1.7	49
38	ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. *Journal of Clinical Investigation*, **2008**, 118, 1632-44	15.9	139
37	Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. *Journal of the American College of Cardiology*, **2007**, 49, 698-705	15.1	72
36	Increased Rho kinase activity in a Taiwanese population with metabolic syndrome. *Journal of the American College of Cardiology*, **2007**, 49, 1619-1624	15.1	81
35	Safety and efficacy of statins in Asians. *American Journal of Cardiology*, **2007**, 99, 410-4	3	166
34	Does it matter whether or not a lipid-lowering agent inhibits Rho kinase?. *Current Atherosclerosis Reports*, **2007**, 9, 384-8	6	3
33	Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?. *Circulation*, **2007**, 115, 1615-21	16.7	50

32	Rho kinase (ROCK) inhibitors. *Journal of Cardiovascular Pharmacology*, **2007**, 50, 17-24	3.1	299
31	Physiological role of ROCKs in the cardiovascular system. *American Journal of Physiology - Cell Physiology*, **2006**, 290, C661-8	5.4	307
30	Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. *Circulation Research*, **2006**, 99, 1426-32	15.7	143
29	Requirement of Rac1 in the development of cardiac hypertrophy. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 7432-7	11.5	227
28	Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. *Stroke*, **2005**, 36, 2251-7	6.7	308
27	Pleiotropic effects of statins. *Annual Review of Pharmacology and Toxicology*, **2005**, 45, 89-118	17.9	1303
26	Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. *American Journal of Cardiology*, **2005**, 96, 24F-33F	3	200
25	Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. *Circulation*, **2005**, 112, 2959-65	16.7	176
24	Rho GTPases, statins, and nitric oxide. *Circulation Research*, **2005**, 97, 1232-5	15.7	383
23	Acute augmentation of cerebral blood flow by rho-kinase inhibitors in focal cerebral ischemia is dependent on endothelial nitric oxide synthase. *Journal of Cerebral Blood Flow and Metabolism*, **2005**, 25, S3-S3	7.3	
22	Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2004**, 24, 1842-7	9.4	289
21	Statin therapy for cardiac hypertrophy and heart failure. *Journal of Investigative Medicine*, **2004**, 52, 248-53	2.9	35
20	Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. *Circulation*, **2003**, 108, 839-43	16.7	349
19	Long-term statin use and psychological well-being. *Journal of the American College of Cardiology*, **2003**, 42, 690-7	15.1	107
18	Role of statin pleiotropism in acute coronary syndromes and stroke. *International Journal of Clinical Practice, Supplement*, **2003**, 51-7		6
17	Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. *Circulation*, **2002**, 106, 57-62	16.7	421
16	Statins and ischemic stroke. *Atherosclerosis Supplements*, **2002**, 3, 21-5	1.7	13
15	Beyond lipid lowering: the role of statins in vascular protection. *International Journal of Cardiology*, **2002**, 86, 5-18	3.2	205

14	Isoprenoids as mediators of the biological effects of statins. *Journal of Clinical Investigation*, **2002**, 110, 285-288	15.9	307
13	Isoprenoids as mediators of the biological effects of statins. *Journal of Clinical Investigation*, **2002**, 110, 285-8	15.9	138
12	Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. *Journal of Clinical Investigation*, **2001**, 108, 1429-37	15.9	337
11	Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. *Journal of Cerebral Blood Flow and Metabolism*, **2000**, 20, 709-17	7.3	123
10	Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. *American Journal of Physiology - Heart and Circulatory Physiology*, **2000**, 279, H2649-57	5.2	70
9	Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. *Circulation Research*, **2000**, 87, 19-25	15.7	159
8	3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). *Journal of Biological Chemistry*, **1999**, 274, 21926-31	5.4	299
7	The inhibition of endothelial activation by unsaturated fatty acids. *Lipids*, **1999**, 34 Suppl, S191-4	1.6	29
6	Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. *Circulation*, **1998**, 97, 1129-35	16.7	1558
5	Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. *Journal of Biological Chemistry*, **1998**, 273, 24266-71	5.4	802
4	Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. *Journal of Biological Chemistry*, **1997**, 272, 31725-9	5.4	294
3	Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. *Journal of Biological Chemistry*, **1995**, 270, 319-24	5.4	389
2	Statins1668-1673		
1	Steroid Hormones1674-1681		